Abstract
Ovarian hyperstimulation syndrome (OHSS) is brought about by overstimulating the ovaries with gonadotrophins, whether during ovulation induction or so-called controlled ovarian hyperstimulation before intra-uterine insemination (IUI) or IVF. It is a purely iatrogenic condition which is largely preventable and often foreseeable. Those at risk to develop OHSS are young, lean and/or have polycystic ovaries, high serum AMH concentrations and a high antral follicle count and patients who have had OHSS in a previous cycle. For ovulation induction only a low-dose gonadotrophin protocol should be used as this will eliminate the incidence of OHSS. For IVF in patients predicted to be at high risk for OHSS, a GnRH antagonist protocol is recommended with the use of a GnRH agonist trigger. OHSS does not occur if hCG is withheld and it may be classified as early, due solely to the hCG injection or late, due to the added effect of hCG secreted by the developing pregnancy. Monitoring, according to the severity of the symptoms, should include fluid and electrolyte balance with detailed recording of fluid input and output, measurement of the extent of intravascular volume decrease including frequent measurements of haematocrit and arterial pressure. Central venous pressure measurement is essential for the more severe cases. Baseline renal and liver function tests should be monitored. Treatment is supportive, according to severity, mainly re-hydration and the maintenance of intravascular fluid volume and blood volume expanders when indicated. Relief of ascites and pleural effusions may be necessary.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY. 1,500 IU human chorionic gonadotropin administerd at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2010;93:847–54.
Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a ‘freeze-all’ strategy: a prospective multicentric study. Fertil Steril. 2011;95:2029–33.
Leitao VM, Moroni RM, Seko LM, Nastri CO, Martins WP. Carbergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2014;101:664–75.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Homburg, R. (2014). Ovarian Hyperstimulation Syndrome. In: Ovulation Induction and Controlled Ovarian Stimulation. Springer, Cham. https://doi.org/10.1007/978-3-319-05612-8_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-05612-8_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-05611-1
Online ISBN: 978-3-319-05612-8
eBook Packages: MedicineMedicine (R0)